DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Serotonin-norepinephrine reuptake
inhibitors, 405–407, 408
adverse effects of, 411
drug interactions with, 412
Serotonin receptor agonists, 344–350,
1326–1327
absorption, fate, and excretion of,
346
history of, 345
mechanism of action, 345–346
in migraine, 346–347
pharmacological properties, 345
Serotonin receptor antagonists,
350–351, 407, 408
adverse effects of, 411
drug interactions with, 412
Serotonin syndrome, 351
Serotonin transporter polymorphism,
160t
Serotonin transporter (SERT), 116
SERT. See Serotonin transporter
(SERT)
Sertaconazole, 1588, 1817
Sertindole
dosage of, 426t
potencies at neurotransmitter
receptors, 427t
side effects of, 426t
Sertraline
arrhythmias caused by, 832
disposition of, 409t
pharmacokinetics of, 1886t
potencies
at human transporters for
monamine neurotransmitters,
406t
at neurotransmitter receptors, 410t
Serum sickness, 76
H 1
-receptor antagonists for, 922
Sevelamer, 19
Sevoflurane
clinical uses of, 550
pharmacokinetics of, 550
side effects of, 550–551
cardiovascular, 550
gastrointestinal, 551
hepatic, 551
muscular, 550
neurological, 550
renal, 551
respiratory, 550
Sex hormones, opioids and, 495
Sexual function, ethanol and, 638–639
Sexual infantilism, 1121, 1838
Sexually transmitted disease (STD), in
females, 1841, 1842t
Sexual maturation, induction, 1838
Shock
histamine, 917
sympathomimetic drugs for, 301
Short-loop negative feedback
mechanism, and renin
release, 723f, 724
Short stature, growth hormone for,
1838
Sialic acid storage disease, 102t
Side effects of drugs. See also Adverse
reactions
difficulty in detecting, 10
Signa, in prescription, 1879
Signal amplification, 52
Signal integration, 52
Signal transduction pathway,
51–52
Sildenafil, 1061
effects on optic nerve, 1792
for heart failure, 805
and nitrates, interactions,
758–759
pharmacokinetics of, 1886t
Silodosin, 306f, 307
Silver sulfadiazine, pharmacological
properties of, 1466
Simethicone, 1347
Simvastatin, 893, 894
absorption, fate, and excretion of,
895–896
chemistry of, 894
dosage of, required to achieve
reduction in LDL-C, 895t
pharmacokinetics of, 1887t
structure of, 893f
therapeutic uses of, 897
in children, 898
SINEQUAN (doxepin hydrochloride),
921t
Single-nephron glomerular filtration
rate (SNGFR), 671–673
Single nucleotide polymorphisms
(SNPs), 145, 147f, 148
Sinoatrial node, in autonomic nervous
system, 178t
Sinoatrial (SA) node, acetylcholine
and, 221
Sinus bradycardia
angina pectoris with, recommended
treatment for, 769t
drug-induced, 821t
Sinus tachycardia
angina pectoris with, recommended
treatment for, 769t
drug-induced, 821t
Sirolimus, 1012–1013, 1743
endovascular stents eluting, 772
pharmacokinetics of, 1887t
structure of, 1744
Sitagliptin, 1264–1265
pharmacokinetics of, 1887t
Sitosterolemia, 104t
Sjögren’s syndrome, xerostomia and,
224
Skeletal muscle
acetylcholinesterase and, 188
adrenocorticosteroids and, 1221
epinephrine and, 286
ethanol and, 636–637
neuromuscular blocking agents and,
258–261
Skeletal organization, 1285
Skin
bacterial infections, 1817
diseases, non-pharmacological
therapy, 1803
infestations, agents used to treat,
1818–1819
lithium and, effects on, 449
necrosis, oral anticoagulant-induced,
864
opioids and, 498
premalignant lesions of, drugs for,
1668t–1670t
structure and function of,
1803–1804, 1804f, 1805f
in topical application of drugs, 23
in transdermal administration, 21
viral infections, 1818
Skin cancer, nonmelanoma,
photochemotherapy for,
1815
Skin rash, angiotensin converting
enzyme inhibitors and, 736
SLC. See Solute carrier (SLC)
trasporters
Sleep
amphetamines and, 298
barbiturates and, 472
benzodiazepines and, 460–461
muscarinic antagonists and, 230
Sleep-wakefulness cycle, 5-HT and, 343
Small molecules
as angiogenesis inhibitors, 1739
antitumor activity, mechanism of
action of, 1731
Smoking
cessation, 272
and dyslipidemia treatment, 890
and risk for coronary heart disease,
887t
2071
INDEX